- Home
- SOHO vs CVKD Comparison
SOHO vs CVKD Comparison
Compare SOHO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOHO
- CVKD
- Stock Information
- Founded
- SOHO 2004
- CVKD 2022
- Country
- SOHO United States
- CVKD United States
- Employees
- SOHO N/A
- CVKD N/A
- Industry
- SOHO Real Estate Investment Trusts
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- SOHO Real Estate
- CVKD Health Care
- Exchange
- SOHO Nasdaq
- CVKD Nasdaq
- Market Cap
- SOHO 27.2M
- CVKD 26.3M
- IPO Year
- SOHO 2004
- CVKD 2023
- Fundamental
- Price
- SOHO $1.01
- CVKD $14.53
- Analyst Decision
- SOHO Hold
- CVKD Strong Buy
- Analyst Count
- SOHO 1
- CVKD 2
- Target Price
- SOHO $1.50
- CVKD $46.00
- AVG Volume (30 Days)
- SOHO 126.6K
- CVKD 72.2K
- Earning Date
- SOHO 11-12-2024
- CVKD 11-07-2024
- Dividend Yield
- SOHO N/A
- CVKD N/A
- EPS Growth
- SOHO N/A
- CVKD N/A
- EPS
- SOHO N/A
- CVKD N/A
- Revenue
- SOHO $179,860,606.00
- CVKD N/A
- Revenue This Year
- SOHO N/A
- CVKD N/A
- Revenue Next Year
- SOHO $0.70
- CVKD N/A
- P/E Ratio
- SOHO N/A
- CVKD N/A
- Revenue Growth
- SOHO 3.98
- CVKD N/A
- 52 Week Low
- SOHO $0.97
- CVKD $5.40
- 52 Week High
- SOHO $1.65
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- SOHO 35.82
- CVKD 48.08
- Support Level
- SOHO $1.02
- CVKD $14.07
- Resistance Level
- SOHO $1.09
- CVKD $19.97
- Average True Range (ATR)
- SOHO 0.07
- CVKD 1.78
- MACD
- SOHO -0.03
- CVKD -0.38
- Stochastic Oscillator
- SOHO 2.50
- CVKD 16.58
About SOHO Sotherly Hotels Inc.
Sotherly Hotels Inc is engaged in Hotel operations. The company is a self-managed and self-administered lodging real estate investment trust that was formed to own, acquire, renovate, and reposition full-service, upscale, and upper-upscale hotel properties located in primary markets in the mid-Atlantic and southern United States. It generates revenue through the rooms, food, beverage, and other services. Geographically, the group has its presence in the regions of Florida, Georgia, Indiana, Maryland, North Carolina, Pennsylvania, Texas, and Virginia.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.